Better Discount To Bylvay £255,000 List Price Sways England’s NICE
Bylvay, the first licensed treatment for the rare liver condition PFIC, is cost effective, health technology assessment body NICE now says of the Albireo Pharma drug.
You may also be interested in...
The SMC, Scotland’s health technology appraisal body, wants more data for Albireo Pharma’s ultra-orphan Bylvay and Novartis’s rare disease drug Adakveo.
Health technology assessment body NICE has also issued guidances rejecting three products.
This is an update of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the EU, and updates on EU marketing authorization changes recommended by the CHMP.